Abstract:OBJECTIVE:To evaluate long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy using optical coherence tomography. METHODS:A retrospective, interventional case series. Thirty-five eyes of 32 patients (35 eyes) with chronic central serous chorioretinopathy were included, with CSC durations from 6 to 60 months. Patients treated with half-dose verteporfin (3 mg/m(2)) PDT were followed up for 24 months. Best-corrected visual acuity (BCVA), fluorescein angiography (FA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT) pre and post-treatment were all examined to observe the anatomic and functional changes. OCT findings highlighted the alterations of the ellipsoid zone (EZ), the interdigitation zone (IZ) and the central neural retina thickness (CNT) from 3 month to 24 month post-treatment. Regression analysis was applied to determine the correlation between the visual function (BCVA) and structure status (EZ, IZ, CNT). RESULTS:Thirty-five eyes of 32 patients with chronic CSC were treated with half-dose PDT. The logMAR BCVA was 0.53±0.36 at baseline, 0.49±0.39 at 3 months and 0.15±0.38 at 24 months post-PDT. There was no statistical significance between baseline and 3 month BCVA (t=1.952, P>0.05). There existed statistical significance between baseline and 24 month BCVA(t=10.761, P<0.01) as well as 3month and 24 month BCVA(t=8.930, P<0.01). OCT demonstrated the recovery of EZ and IZ. Statistical differences of EZ and IZ integrity degree were found between the 3 month and 24 month (Z=-3.419, -4.082, P<0.01). The mean CNT was (126.8±34.9) μm at baseline. And it kept constant at 3 month [(125.6±34.3)μm] and the 24 month visit [(124.8±35.1)μm]. No statistical significance was found between any two values (t=-1.830, -1.569, 0.793, P>0.05). At baseline, 3 month and 24 month, there was negative correlation between logMAR BCVA and CNT (β=-0.604, -0.634, -0.685, P<0.01) . At 3 month and 24 month, negative correlation between logMAR BCVA and EZ as well as logMAR BCVA and IZ were also found(β=-0.376, -0.394, -0.628, -0.496, P<0.05). A complete resolution of subretinal fluid was noted in 94.3% eyes at 3 month, further increased to 100% eyes at 24 month. The mean session of PDT was 1.03±0.17. CONCLUSIONS:Half-dose PDT was safe and effective for chronic CSC both functionally and morphologically in the long term. Visual benefits may not appear in a short run, yet became remarkable in a long run. Visual benefits might be attributed to recovery of EZ and IZ.

Reply to the comment on "Short term choroidal microvascular changes following photodynamic therapy in chronic central serous chorioretinopathy"

Choroidal and Choriocapillaris Changes after Photodynamic Therapy and Subthreshold Micropulse Laser Treatment for Central Serous Chorioretinopathy

Subfoveal Choroidal Thickness after Photodynamic Therapy in Patients with Acute Idiopathic Central Serous Chorioretinopathy

[Observation on Long-Term Efficacy of Half-Dose Photodynamic Therapy with Chronic Central Serous Chorioretinopathy Using Optical Coherence Tomography].

Three-Year Follow-Up Detecting Choroidal Neovascularization with Swept Source Optical Coherence Tomography Angiography (SS-OCTA) after Successful Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Clinical predictive factors and imaging biomarkers of treatment response to half dose PDT in patients with chronic central serous chorioretinopathy

Observation on the Efficacy of Conbercept for Chronic Central Serous Chorioretinopathy

Short-Term Retinal Sensitivity and Metamorphopsia Changes following Half-Fluence Photodynamic Therapy in Central Serous Chorioretinopathy

Changes in the Foveal Outer Nuclear Layer of Central Serous Chorioretinopathy Patients over the Disease Course and Their Response to Photodynamic Therapy

Quantitative analysis of choroidal blood flow parameters in optical coherence tomography and angiography in central serous chorioretinopathy

Use of a Fundus Image-Based Titration Strategy for Selective Retina Therapy for Central Serous Chorioretinopathy

Threshold Thickness of Foveal Outer Nuclear Layer Associated with Outcomes of Photodynamic Therapy in Central Serous Chorioretinopathy

Optical coherence tomography angiography–guided vs indocyanine green angiography–guided half-dose photodynamic therapy for acute central serous chorioretinopathy: 6-month randomized trial results

Changes in Retinal and Choroidal Vascularity in Eyes with Acute Central Serous Chorioretinopathy Using Optical Coherence Tomography Angiography

Choroidal Vessel and Stromal Volumetric Analysis After Photodynamic Therapy or Focal Laser for Central Serous Chorioretinopathy

Changes in the outer nuclear layer and choroidal vascularity during the manifest and quiescent phases of acute central serous chorioretinopathy

[Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].

Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy

Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective study

Comparison of two laser power levels in the subthreshold MicroPulse Yellow Laser Treatment of Acute Central Serous Chorioretinopathy

Analysis of Cytokine Levels Based on Optical Coherence Tomography Findings in Acute and Chronic Central Serous Chorioretinopathy